Eisai Files Application Seeking Additional Indication for ARICEPT in US.Tokyo, Japan, Sept 3, 2005 - (JCNN JCNN Japan Corporate News Network ) - Eisai announced on September 1 that its US subsidiary Eisai Medical Research has filed a supplemental New Drug Application (sNDA) for ARICEPT (donepezil HC1 tablet) with the U.S. Food and Drug Administration (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ). Eisai expects that ARICEPT will become applicable for the treatment of severe Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . Currently, ARICEPT is available in 76 countries. The company aims for ARICEPT sales of 185 billion yen ($1.7 bil) worldwide in fiscal 2005. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion